Results 191 to 200 of about 180,771 (310)

The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab. [PDF]

Discov Oncol
Hanáčková V, Grohmann J, Urbánková H, Študentová H, Buriánková E, Henzlová L, Papajík T, Bachanová V, Procházka V.   +8 more
europepmc   +1 more source

Recurrence of Non-Hodgkin Lymphoma at the Insulin Injection Site: Case Report

Orhan Türken, Şükrü Yıldırım, Gözde Şanlı, Rahmi Çubuk, G. Jarrar   +4 more
openalex   +2 more sources

Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma. [PDF]

Oncol Lett
Zhang X, Li G, Liu F, Shi R, Wen J, Wu W, Dai J.   +6 more
europepmc   +1 more source

Non-Hodgkin Lymphoma Presenting as Tonsillitis

, 2020
Lígia Barbosa Torres, Daniel Torres, Ana Cardoso   +2 more
openalex   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Treatment of older patients with Hodgkin lymphoma. [PDF]

Blood Res
Park CH, Cho H, Kim SJ.
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma [PDF]

, 2009
Roland Schmitz, Martin‐Leo Hansmann, Verena Bohle, José I. Martín‐Subero, Sylvia Hartmann, Gunhild Mechtersheimer, Wolfram Klapper, Inga Vater, Maciej Giefing, Stefan Gesk, Jens Stanelle, Reiner Siebert, Ralf Küppers   +12 more
openalex   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Follicular non-Hodgkin lymphoma recurrence in an uncommon site: the lacrimal caruncle. [PDF]

J Surg Case Rep
Ozkul E, Mangan MS, Buttanri IB, Mazmanoglu Atilman S.   +3 more
europepmc   +1 more source